Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2025)

Rani Therapeutics Holdings has reported Depreciation & Amortization (CF) over the past 6 years, most recently at $186000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $186000.0 for Q4 2025, down 30.08% from a year ago — trailing twelve months through Dec 2025 was $900000.0 (down 12.45% YoY), and the annual figure for FY2025 was $900000.0, down 12.45%.
  • Depreciation & Amortization (CF) for Q4 2025 was $186000.0 at Rani Therapeutics Holdings, down from $223000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for RANI hit a ceiling of $266000.0 in Q4 2024 and a floor of $111000.0 in Q1 2022.
  • Median Depreciation & Amortization (CF) over the past 5 years was $188500.0 (2023), compared with a mean of $189750.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 69.37% in 2023 and later plummeted 30.08% in 2025.
  • Rani Therapeutics Holdings' Depreciation & Amortization (CF) stood at $113000.0 in 2021, then surged by 53.98% to $174000.0 in 2022, then soared by 30.46% to $227000.0 in 2023, then grew by 17.18% to $266000.0 in 2024, then plummeted by 30.08% to $186000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $186000.0 (Q4 2025), $223000.0 (Q3 2025), and $240000.0 (Q2 2025) per Business Quant data.